FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

No narrative content found in resource

Source1

{
  "resourceType": "Parameters",
  "id": "CcServiceOutputParametersExample",
  "meta": {
    "profile": [
      "http://omi.de/fhir/registry/StructureDefinition/CcServiceOutputParameters"
    ]
  },
  "parameter": [
    {
      "name": "cds-card",
      "valueString": "{\"cards\":[{\"summary\":\"3 Possible Clinical Trial(s) have been found. [condition: C71 - Bösartige Neubildung des Gehirns | uicc: I | variants: CDKN2B, MTAP, CDKN2C, TERT, CDKN2A, PTEN, CIC, TP53]\",\"detail\":\"The following Research Studies are recruiting or not yet recruiting and could be considered for the patients condition constellation. CDS Score is calculated by adding weights from different parameters: Diagnosis (1 point), Subtype (1 point), UICC (1 point), Genes (5 points), Adjuvant (1 point), trial is validated (1 point), pathway exists (1 point). Results can be seen in every suggestion. NOTE: This CDS service is currently under development and should not be used for clinical decision making.\\n\",\"indicator\":\"info\",\"source\":{\"label\":\"Community Annotated Trial Search (CATS)\",\"url\":\"https://cats.molit.eu\",\"icon\":\"https://molit.eu/wp-content/uploads/2017/01/favicon.png\"},\"suggestions\":[{\"label\":\"|Title|[Continuous ReAssessment With Flexible ExTension in Rare Malignancies - CRAFT: The NCT-PMO-1602 Phase II Trial](https://cats.molit.eu/details/3397)|\\n| ------ | ------ |\\n|**CDS-Score**|**8**|\\n|\\n|**Search Criteria**|Condition: Bösartige Neubildung des Gehirns, Variants: CDKN2B, MTAP, CDKN2C, TERT, CDKN2A, PTEN, CIC, TP53, Adjuvant: false, Pathway: true|\\n|Intervention|Vemurafenib<br>Cobimetinib<br>Inavolisib<br>Pertuzumab<br>Alectinib<br>Trastuzumab<br>Atezolizumab<br>Alectinib<br>Pertuzumab<br>Trastuzumab biosimilar abp 980<br>Ipatasertib<br>Cobimetinib<br>Trastuzumab<br>Vemurafenib|\\n|Investigated Genes|ERBB2, BRAF, ERBB2, ALK, PIK3CA, AKT1, PTEN|\\n|Is adjuvant|n/a|\\n|Has pathway|true|\\n|Is Validated|false|\\n|Study Sites|Charité - Universitätsmedizin Berlin, Berlin<br>Nationales Centrum für Tumorerkrankungen (NCT), Dresden<br>Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg<br>Universitätsmedizin der Johannes Gutenberg- Universität Mainz, Mainz<br>Universitätsklinikum Tübingen, Medizinische Klinik I, Tübingen<br>Universitätsklinikum Würzburg, Interdisziplinäres Studienzentrum mit ECTU, Würzburg<br>Universitätsklinikum Schleswig-Holstein, Lübeck<br>Klinikum Rechts der Isar der TU München, München<br>Universitätsklinikum Freiburg, Freiburg\",\"uuid\":\"fa3b9083-ce67-45be-80d9-876f95c4d918\"},{\"label\":\"|Title|[Controlled Clinical Trial to Evaluate the Safety and Efficacy of Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma](https://cats.molit.eu/details/16552)|\\n| ------ | ------ |\\n|**CDS-Score**|**3**|\\n|\\n|**Search Criteria**|Condition: Bösartige Neubildung des Gehirns, Validated: true|\\n|Intervention|Stereotactic biopsy<br>Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid|\\n|Investigated Genes|n/a|\\n|Is adjuvant|n/a|\\n|Has pathway|n/a|\\n|Is Validated|true|\\n|Study Sites|Medizinische Fakultät Carl Gustav Carus, Klinik und Poliklinik für Neurochirurgie, Dresden<br>Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Abteilung Funktionelle NC & Stereotaxie, Düsseldorf<br>Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen<br>LMU München, Campus Großhadern, Neurochirurgische Klinik und Poliklinik, München<br>Universitätsklinikum Münster, Klinik und Poliklinik für Neurochirurgie, Münster\",\"uuid\":\"12a6c57a-b4c8-490a-9316-b2e42958834e\"},{\"label\":\"|Title|[Cross-institutional, prospective, open label, single group basket study of combined CRAF and MEK inhibition in advanced-stage malignancies harboring BRAF mutations with impaired kinase activity (SORATRAM)](https://cats.molit.eu/details/7059)|\\n| ------ | ------ |\\n|**CDS-Score**|**3**|\\n|\\n|**Search Criteria**|Condition: Bösartige Neubildung des Gehirns, Validated: true, Adjuvant: false|\\n|Intervention|Sorafenib<br>Trametinib|\\n|Investigated Genes|BRAF|\\n|Is adjuvant|n/a|\\n|Has pathway|n/a|\\n|Is Validated|true|\\n|Study Sites|Heidelberg University Clinic, Heidelberg<br>Mainz Universitätsmedizin, Mainz<br>Frankfurt Am Main, null\",\"uuid\":\"7f1c8d6b-3cbb-4317-8edb-842880cd27b5\"}]}],\"selectionBehavior\":\"at-most-one\",\"links\":null}"
    }
  ]
}